Merrill keeps Alkermes at buy

Alkermes Inc. was maintained at a buy rating by Merrill Lynch analyst Hari Sambasivam. The company will announce its third-quarter 2006 results on Feb. 7. Merrill's estimates for the quarter include total revenues of $43.3 million, total expenses of $44.8 million, and pro-forma earnings per share of $0.05, compared to $23.6 million, $31.9 million and $0.10 respectively for the third quarter of 2005. Consensus earnings per share for the quarter is $0.08. Shares of the Cambridge, Mass., pharmaceutical company were up 3 cents, or 0.13%, at $23.43 on volume of 1,381,896 shares versus the three-month running average of 1,878,180 shares. (Nasdaq: ALKS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.